Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance

Edwards Lifesciences Reports Fourth Quarter Results

February 1, 2017 4:15 PM EST

IRVINE, Calif., Feb. 1, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2016. 

Fourth Quarter and Recent Highlights:

Sales grew 14 percent to $768 million; underlying1 sales were up 15 percent Global Transcatheter Heart Valve Therapy (THVT) sales grew 29 percent to $432 million U.S. THVT sales were up 38 percent EPS was $0.73, an increase of 14... More